Cargando…

Prostate Cancer—PET Imaging Update

SIMPLE SUMMARY: The imaging of prostate cancer has evolved over the last few decades with molecular imaging, especially Positron Emission Tomography (PET) replacing conventional CT and MRI in patients with prostate cancer recurrence. These recent advances in PET imaging have allowed for a better loc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jetty, Sankarsh, Loftus, James Ryan, Patel, Abhinav, Gupta, Akshya, Puri, Savita, Dogra, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913636/
https://www.ncbi.nlm.nih.gov/pubmed/36765754
http://dx.doi.org/10.3390/cancers15030796
_version_ 1784885474428452864
author Jetty, Sankarsh
Loftus, James Ryan
Patel, Abhinav
Gupta, Akshya
Puri, Savita
Dogra, Vikram
author_facet Jetty, Sankarsh
Loftus, James Ryan
Patel, Abhinav
Gupta, Akshya
Puri, Savita
Dogra, Vikram
author_sort Jetty, Sankarsh
collection PubMed
description SIMPLE SUMMARY: The imaging of prostate cancer has evolved over the last few decades with molecular imaging, especially Positron Emission Tomography (PET) replacing conventional CT and MRI in patients with prostate cancer recurrence. These recent advances in PET imaging have allowed for a better localization of disease recurrence, and a better characterization of disease extent. Beyond localization and characterization, new uses for PET imaging have emerged, with PET agents now playing a role in assessing the response to treatment at the receptor level, and also helping to determine patient prognosis and survival. ABSTRACT: Prostate cancer is the most common non-dermatologic cancer in men, and one of the leading causes of cancer-related mortality. The incidence of prostate cancer increases precipitously after the age of 65 and demonstrates variable aggressiveness, depending on its grade and stage at diagnosis. Despite recent advancements in prostate cancer treatment, recurrence is seen in 25% of patients. Advancements in prostate cancer Positron Emission Tomography (PET) molecular imaging and recent United States Food and Drug Administration (FDA) approvals have led to several new options for evaluating prostate cancer. This manuscript will review the commonly used molecular imaging agents, with an emphasis on Fluorine-18 fluciclovine (Axumin) and PSMA-ligand agents, including their protocols, imaging interpretation, and pitfalls.
format Online
Article
Text
id pubmed-9913636
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99136362023-02-11 Prostate Cancer—PET Imaging Update Jetty, Sankarsh Loftus, James Ryan Patel, Abhinav Gupta, Akshya Puri, Savita Dogra, Vikram Cancers (Basel) Review SIMPLE SUMMARY: The imaging of prostate cancer has evolved over the last few decades with molecular imaging, especially Positron Emission Tomography (PET) replacing conventional CT and MRI in patients with prostate cancer recurrence. These recent advances in PET imaging have allowed for a better localization of disease recurrence, and a better characterization of disease extent. Beyond localization and characterization, new uses for PET imaging have emerged, with PET agents now playing a role in assessing the response to treatment at the receptor level, and also helping to determine patient prognosis and survival. ABSTRACT: Prostate cancer is the most common non-dermatologic cancer in men, and one of the leading causes of cancer-related mortality. The incidence of prostate cancer increases precipitously after the age of 65 and demonstrates variable aggressiveness, depending on its grade and stage at diagnosis. Despite recent advancements in prostate cancer treatment, recurrence is seen in 25% of patients. Advancements in prostate cancer Positron Emission Tomography (PET) molecular imaging and recent United States Food and Drug Administration (FDA) approvals have led to several new options for evaluating prostate cancer. This manuscript will review the commonly used molecular imaging agents, with an emphasis on Fluorine-18 fluciclovine (Axumin) and PSMA-ligand agents, including their protocols, imaging interpretation, and pitfalls. MDPI 2023-01-28 /pmc/articles/PMC9913636/ /pubmed/36765754 http://dx.doi.org/10.3390/cancers15030796 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jetty, Sankarsh
Loftus, James Ryan
Patel, Abhinav
Gupta, Akshya
Puri, Savita
Dogra, Vikram
Prostate Cancer—PET Imaging Update
title Prostate Cancer—PET Imaging Update
title_full Prostate Cancer—PET Imaging Update
title_fullStr Prostate Cancer—PET Imaging Update
title_full_unstemmed Prostate Cancer—PET Imaging Update
title_short Prostate Cancer—PET Imaging Update
title_sort prostate cancer—pet imaging update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913636/
https://www.ncbi.nlm.nih.gov/pubmed/36765754
http://dx.doi.org/10.3390/cancers15030796
work_keys_str_mv AT jettysankarsh prostatecancerpetimagingupdate
AT loftusjamesryan prostatecancerpetimagingupdate
AT patelabhinav prostatecancerpetimagingupdate
AT guptaakshya prostatecancerpetimagingupdate
AT purisavita prostatecancerpetimagingupdate
AT dogravikram prostatecancerpetimagingupdate